Literature DB >> 10029615

Serum immunoglobulin A from patients with celiac disease inhibits human T84 intestinal crypt epithelial cell differentiation.

T Halttunen1, M Mäki.   

Abstract

BACKGROUND & AIMS: Celiac disease is characterized by disturbed jejunal crypt-villus axis biology with immunoglobulin (Ig) A deposits underlining the epithelium. The aim of this study was to test whether celiac disease serum IgA (reticulin/endomysial autoantibodies) interferes with the mesenchymal-epithelial cell cross-talk.
METHODS: Differentiation of T84 epithelial cells was induced with IMR-90 fibroblasts or transforming growth factor beta in three-dimensional collagen gel cultures. The effects of purified celiac IgA and monoclonal tissue transglutaminase antibodies (CUB7402) were studied by adding the antibodies to the cocultures.
RESULTS: Active celiac disease IgA, reactive for tissue transglutaminase, significantly inhibited T84 epithelial cell differentiation (P < 0.001) and increased epithelial cell proliferation (P = 0.024). Similar effects were obtained with antibodies against tissue transglutaminase.
CONCLUSIONS: Celiac disease-associated IgA class antibodies disturb transforming growth factor beta-mediated fibroblast-epithelial cell cross-talk in this in vitro crypt-villus axis model. This primary finding indicates that celiac disease-specific autoantibodies may also contribute to the formation of the gluten-triggered jejunal mucosal lesion in celiac disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10029615     DOI: 10.1016/s0016-5085(99)70178-2

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  41 in total

Review 1.  Recent advances in the understanding of celiac disease: therapeutic implications for the management of pediatric patients.

Authors:  John H Kwon; Richard J Farrell
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

Review 2.  [Dermatitis herpetiformis. An update of the pathogenesis].

Authors:  M Sárdy; J Tietze
Journal:  Hautarzt       Date:  2009-08       Impact factor: 0.751

Review 3.  Antibodies in celiac disease: implications beyond diagnostics.

Authors:  Sergio Caja; Markku Mäki; Katri Kaukinen; Katri Lindfors
Journal:  Cell Mol Immunol       Date:  2011-01-31       Impact factor: 11.530

Review 4.  Anti-type 2 transglutaminase antibodies as modulators of type 2 transglutaminase functions: a possible pathological role in celiac disease.

Authors:  Stefania Martucciello; Gaetana Paolella; Carla Esposito; Marilena Lepretti; Ivana Caputo
Journal:  Cell Mol Life Sci       Date:  2018-08-22       Impact factor: 9.261

5.  Parallel expression of macrophage metalloelastase (MMP-12) in duodenal and skin lesions of patients with dermatitis herpetiformis.

Authors:  M T Salmela; S L Pender; T Reunala; T MacDonald; U Saarialho-Kere
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

6.  Mutagenesis of the catalytic triad of tissue transglutaminase abrogates coeliac disease serum IgA autoantibody binding.

Authors:  Greg Byrne; Fergus Ryan; John Jackson; Con Feighery; Jacinta Kelly
Journal:  Gut       Date:  2006-08-25       Impact factor: 23.059

Review 7.  Role of transglutaminase 2 in celiac disease pathogenesis.

Authors:  Cornelius Klöck; Thomas R Diraimondo; Chaitan Khosla
Journal:  Semin Immunopathol       Date:  2012-03-22       Impact factor: 9.623

Review 8.  Coeliac disease: an update for pathologists.

Authors:  B C Dickson; C J Streutker; R Chetty
Journal:  J Clin Pathol       Date:  2006-10       Impact factor: 3.411

9.  In vivo targeting of intestinal and extraintestinal transglutaminase 2 by coeliac autoantibodies.

Authors:  I R Korponay-Szabó; T Halttunen; Z Szalai; K Laurila; R Király; J B Kovács; L Fésüs; M Mäki
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

10.  Coeliac disease-specific autoantibodies targeted against transglutaminase 2 disturb angiogenesis.

Authors:  E Myrsky; K Kaukinen; M Syrjänen; I R Korponay-Szabó; M Mäki; K Lindfors
Journal:  Clin Exp Immunol       Date:  2008-02-14       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.